{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:42:27Z","timestamp":1778506947476,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beem.2019.101368","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T11:41:07Z","timestamp":1574768467000},"page":"101368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Primary aldosteronism: Treatment of the disease, and new therapeutic approaches"],"prefix":"10.1016","volume":"34","author":[{"given":"John","family":"Funder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2019.101368_bib1","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: and endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib2","first-page":"711","article-title":"Task force committee on primary aldosteronism the Japan endocrine society. Guidelines for the diagnosis and treatment of primary aldosteronism","volume":"58","author":"Nishikawa","year":"2009","journal-title":"Jpn Endocr Soc Endocrine J 2011"},{"key":"10.1016\/j.beem.2019.101368_bib3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection diagnosis and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2019.101368_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2019.101368_bib6","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1210\/jc.2018-01394","article-title":"Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism","volume":"103","author":"Stowasser","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1365-2362.2011.02531.x","article-title":"High prevalence of autonomous aldosterone secretion among patients with essential hypertension","volume":"41","author":"Gouli","year":"2011","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.beem.2019.101368_bib8","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1210\/jc.2015-1268","article-title":"Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension","volume":"100","author":"Markou","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/eci.12746","article-title":"Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism","volume":"47","author":"Ladurner","year":"2017","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.beem.2019.101368_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","article-title":"Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial","volume":"4","author":"Dekkers","year":"2016","journal-title":"Lancet Diabet Endocrinol"},{"key":"10.1016\/j.beem.2019.101368_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.117.09295","article-title":"Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: pro side of the argument","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2019.101368_bib12","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1210\/jc.2011-0138","article-title":"Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically","volume":"96","author":"Ahmed","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"127","key":"10.1016\/j.beem.2019.101368_bib13","article-title":"A\u00a0novel method: super-selective adrenal venous sampling","author":"Makita","year":"2017","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.beem.2019.101368_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.beem.2019.101368_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.beem.2019.101368_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2019.101368_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.beem.2019.101368_bib18","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/HJH.0000000000001088","article-title":"Guidelines for primary aldosteronism: uptake by primary care physicians in Europe","volume":"34","author":"Mulatero","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.beem.2019.101368_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF01476798","article-title":"Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading","volume":"58","author":"Helber","year":"1980","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.beem.2019.101368_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/507163a","article-title":"The art of science advice to government","volume":"507","author":"Gluckman","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.beem.2019.101368_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.nucmedbio.2018.11.002","article-title":"Development of [(18)F]FAMTO: a novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands","volume":"68\u201369","author":"Bongarzone","year":"2019","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.beem.2019.101368_bib23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1210\/jc.2015-3431","article-title":"A\u00a0novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism","volume":"101","author":"Abe","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","article-title":"Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma","volume":"71","author":"Heinze","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2019.101368_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsmedchemlett.5b00054","article-title":"Discovery of benzimidazole CYP11B2 inhibitors with in\u00a0vivo activity in rhesus monkeys","volume":"6","author":"Hoyt","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.beem.2019.101368_bib26","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2018-01004","article-title":"Targeted molecular characterization of aldosterone-producing adenomas in white Americans","volume":"103","author":"Nanba","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","article-title":"Genetic Characteristics of aldosterone-producing adenomas in blacks","volume":"73","author":"Nanba","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2019.101368_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1440-1681.1996.tb02789.x","article-title":"Production of 18-oxo-cortisol in subtypes of primary aldosteronism","volume":"23","author":"Stowasser","year":"1996","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.beem.2019.101368_bib29","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1161\/HYPERTENSIONAHA.114.04453","article-title":"Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism","volume":"65","author":"Satoh","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2019.101368_bib30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/HYPERTENSIONAHA.118.12064","article-title":"18-Oxocortisol synthesis in aldosterone-producing adrenocortical adenoma and significance of KCNJ5 mutation status","volume":"73","author":"Tezuka","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2019.101368_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1373\/clinchem.2015.251199","article-title":"Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism","volume":"62","author":"Eisenhofer","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.beem.2019.101368_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jsbmb.2019.01.008","article-title":"Classification of microadenomas in patients with primary aldosteronism by steroid profiling","volume":"189","author":"Yang","year":"2019","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.beem.2019.101368_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.tvir.2010.02.004","article-title":"Percutaneous ablation of adrenal tumors","volume":"13","author":"Venkatesan","year":"2010","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.beem.2019.101368_bib34","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","article-title":"Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction","volume":"54","author":"Mihailidou","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2019.101368_bib35","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101368_bib36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bcp.13152","article-title":"Spironolactone use and risk of incident cancers: a retrospective, matched cohort study","volume":"83","author":"Mackenzie","year":"2017","journal-title":"Br J Clin Pharmacol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:02Z","timestamp":1761497762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X19301198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521690X19301198"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2019.101368","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary aldosteronism: Treatment of the disease, and new therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2019.101368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101368"}}